We have located links that may give you full text access.
Multimer Detection System-Oligomerized Amyloid Beta (MDS-OA β ): A Plasma-Based Biomarker Differentiates Alzheimer's Disease from Other Etiologies of Dementia.
With emerging amyloid therapies, documentation of the patient's amyloid status to confirm the etiology of a clinical diagnosis is warranted prior to instituting amyloid-based therapy. The Multimer Detection System-Oligomeric Amyloid- β (MDS-OA β ) is a noninvasive blood-based biomarker utilized to measure A β oligomerization tendency. We determined the difference in MDS-OA β ratio across the groups: (a) no cognitive impairment or subjective cognitive impairment (NCI/SCI), (b) Alzheimer's disease (AD), (c) non-AD, and (d) mixed Alzheimer's disease-Vascular dementia (AD-VaD). MDS-OA β level was not significantly different between AD and mixed AD-VaD, but both groups were significantly different from the NCI/SCI and from the non-AD group. An MDS-OA β level of >1 could potentially indicate clinical variants of AD or mixed pathology (AD-VaD).
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app